The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells
Published 2011 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 156, Issue 5, Pages 633-642
Publisher
Wiley
Online
2011-12-23
DOI
10.1111/j.1365-2141.2011.08983.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
- (2010) G. Dasmahapatra et al. BLOOD
- The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells
- (2010) Sonja Mandl-Weber et al. BRITISH JOURNAL OF HAEMATOLOGY
- A novel effect of DNA methyltransferase and histone deacetylase inhibitors : NFκB inhibition in malignant myeloblasts
- (2010) Claire Fabre et al. CELL CYCLE
- A work in progress: The clinical development of histone deacetylase inhibitor
- (2010) Silvia Marsoni et al. Epigenetics
- The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells
- (2010) Shuhong Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma
- (2009) Monica Galli et al. ANNALS OF HEMATOLOGY
- Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
- (2009) M. Gupta et al. BLOOD
- Histone deacetylase inhibitors as anti-neoplastic agents
- (2009) Nicolas Batty et al. CANCER LETTERS
- Bortezomib Alone or in Combination with the Histone Deacetylase Inhibitor JNJ-26481585: Effect on Myeloma Bone Disease in the 5T2MM Murine Model of Myeloma
- (2009) Sarah Deleu et al. CANCER RESEARCH
- Phase I Study of Vorinostat in Combination with Bortezomib for Relapsed and Refractory Multiple Myeloma
- (2009) A. Badros et al. CLINICAL CANCER RESEARCH
- HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity
- (2009) Vivek Sharma et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Multiple myeloma
- (2009) Marc S Raab et al. LANCET
- The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models
- (2009) S Deleu et al. LEUKEMIA
- Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib
- (2009) Constantine S. Mitsiades et al. SEMINARS IN HEMATOLOGY
- Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma
- (2008) A. Zollinger et al. BLOOD
- Acetylation Is Indispensable for p53 Activation
- (2008) Yi Tang et al. CELL
- Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma
- (2008) Ken-ichi Kitazoe et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
- (2008) Paul Richardson et al. LEUKEMIA & LYMPHOMA
- KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling
- (2008) Rentian Feng et al. MOLECULAR CANCER THERAPEUTICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now